GlassScriptPhysician profile
Michael C Schneider
NPI 1326022278
$478.28
in general payments reported to CMS, 2019-2025
11 companies · $56.96 in 2025
The $56.96 reported for 2025 was less than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.83 · 2021: $185 · 2023: $18.51 · 2024: $203 · 2025: $56.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.80 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $60.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $52.39 | 2024 | Strensiq, Koselugo |
| Bausch & Lomb Americas INC. | $24.23 | 2024 | Xiidra, Miebo |
| Krystal Biotech INC | $24.19 | 2025 | Vyjuvek |
| Harrow Eye, LLC | $21.62 | 2024 | Vevye |
| Takeda Pharmaceuticals U.S.A., INC. | $18.51 | 2023 | Vpriv |
| Rhythm Pharmaceuticals, INC. | $15.71 | 2024 | Imcivree |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.